Skip to main content
. 2016 Jan 11;3(1):e000108. doi: 10.1136/bmjresp-2015-000108

Figure 1.

Figure 1

Registry organisational chart. The Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry will be administered by Committees with representation from Duke Clinical Research Institute (DCRI), Boehringer Ingelheim (BI) and site investigators (sites).